The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 trial.
 
Moran Amit
No Relationships to Disclose
 
Robert Saddawi-Konefka
No Relationships to Disclose
 
Shorook Naara
No Relationships to Disclose
 
Neal Akhave
Honoraria - American Society of Clinical Oncology; ASCO
Consulting or Advisory Role - Adcendo; Genmab/Seagen
Research Funding - AVEO (Inst); Bicara Therapeutics (Inst); Innocare (Inst); Merus (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - American Society of Clinical Oncology; American Society of Clinical Oncology; Genmab/Seagen
 
Luana Guimaraes de Sousa
Consulting or Advisory Role - Coherus Biosciences
Research Funding - Agenus (Inst); Regeneron (Inst)
 
Frederico Netto
No Relationships to Disclose
 
Sonali Jindal
No Relationships to Disclose
 
Shamima Akhter
No Relationships to Disclose
 
Tongxin Xie
No Relationships to Disclose
 
Yen Vu
No Relationships to Disclose
 
James Allison
No Relationships to Disclose
 
Jeffrey Myers
No Relationships to Disclose
 
Mark Chambers
No Relationships to Disclose
 
Humam Kadara
No Relationships to Disclose
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Akoya Biosciences; Akoya Biosciences (I); Apricity Health; Apricity Health (I); Bectas (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Matrisome; Oncolytics; Osteologic; Osteologic Therpeutics (I); PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)